Leap Therapeutics Dirección

Dirección controles de criterios 3/4

El CEO de Leap Therapeutics' es Doug Onsi , nombrado en Jan 2011, tiene una permanencia de 13.42 años. compensación anual total es $1.53M, compuesta por 43.6% salario y 56.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.19% de las acciones de la empresa, por valor de €132.96K. La antigüedad media del equipo directivo y de la junta directiva es de 4.2 años y 7.4 años, respectivamente.

Información clave

Doug Onsi

Chief Executive Officer (CEO)

US$1.5m

Compensación total

Porcentaje del salario del CEO	43.6%
Permanencia del CEO	13.4yrs
Participación del CEO	0.2%
Permanencia media de la dirección	4.2yrs
Promedio de permanencia en la Junta Directiva	7.4yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Doug Onsi en comparación con los beneficios de Leap Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$53m
Dec 31 2023	US$2m	US$669k	-US$81m
Sep 30 2023	n/a	n/a	-US$81m
Jun 30 2023	n/a	n/a	-US$82m
Mar 31 2023	n/a	n/a	-US$86m
Dec 31 2022	US$2m	US$637k	-US$55m
Sep 30 2022	n/a	n/a	-US$53m
Jun 30 2022	n/a	n/a	-US$49m
Mar 31 2022	n/a	n/a	-US$42m
Dec 31 2021	US$2m	US$596k	-US$41m
Sep 30 2021	n/a	n/a	-US$37m
Jun 30 2021	n/a	n/a	-US$32m
Mar 31 2021	n/a	n/a	-US$29m
Dec 31 2020	US$2m	US$513k	-US$38m
Sep 30 2020	n/a	n/a	-US$39m
Jun 30 2020	n/a	n/a	-US$40m
Mar 31 2020	n/a	n/a	-US$42m
Dec 31 2019	US$817k	US$400k	-US$33m
Sep 30 2019	n/a	n/a	-US$24m
Jun 30 2019	n/a	n/a	-US$22m
Mar 31 2019	n/a	n/a	-US$21m
Dec 31 2018	US$682k	US$400k	-US$23m
Sep 30 2018	n/a	n/a	-US$31m
Jun 30 2018	n/a	n/a	-US$31m
Mar 31 2018	n/a	n/a	-US$31m
Dec 31 2017	US$3m	US$397k	-US$30m

Compensación vs. Mercado: La compensación total de Doug($USD1.53M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD434.45K).

Compensación vs. Ingresos: La compensación de Doug ha sido consistente con los resultados de la empresa en el último año.

CEO

Doug Onsi (55 yo)

13.4yrs

Permanencia

US$1,534,507

Compensación

Mr. Douglas E. Onsi, also known as Doug, J.D., serves as Director at Leap Therapeutics, Inc. since March 18, 2020. He serves as Managing Director of HCV Management VIII, LLC (formerly known as HealthCare V...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Douglas Onsi	CFO, General Counsel	13.4yrs	US$1.53m	0.19% $ 133.4k
Augustine Lawlor	Chief Operating Officer	8.4yrs	US$1.00m	0.013% $ 9.2k
Cynthia Sirard	Chief Medical Officer	4.2yrs	US$999.40k	0.013% $ 9.1k
Jason Baum	Chief Scientific Officer	1.2yrs	sin datos	sin datos
Mark O'Mahony	Chief Manufacturing Officer	4.2yrs	sin datos	0.013% $ 9.1k
Christine Granfield	VP and Head of Regulatory Affairs & Quality	3.8yrs	sin datos	sin datos

4.2yrs

Permanencia media

54.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 5MC se considera experimentado (4.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Douglas Onsi	CFO, General Counsel	4.3yrs	US$1.53m	0.19% $ 133.4k
Christopher Mirabelli	Chairman	13.4yrs	US$744.18k	0.013% $ 9.2k
James Cavanaugh	Independent Director	8.4yrs	US$126.62k	0% $ 0
Thomas Dietz	Lead Independent Director	8.4yrs	US$188.86k	0% $ 0
Nissim Mashiach	Independent Director	7.4yrs	US$118.24k	0% $ 0
Joseph Loscalzo	Independent Director	8.4yrs	US$112.12k	0% $ 0
William Li	Independent Director	7.4yrs	US$121.62k	0% $ 0
Carl Nathan	Member of Scientific Advisory Board	no data	sin datos	sin datos
Richard Schilsky	Independent Director	1.8yrs	US$112.12k	0% $ 0
Richard Brian Gaynor	Member of Scientific Advisory Board	3.4yrs	sin datos	sin datos
David Tuveson	Member of Scientific Advisory Board	no data	sin datos	sin datos
Andrew Nixon	Member of Scientific Advisory Board	3.4yrs	sin datos	sin datos

7.4yrs

Permanencia media

70yo

Promedio de edad

Junta con experiencia: La junta directiva de 5MC se considera experimentada (7.4 años de antigüedad promedio).

Leap Therapeutics Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Leap Therapeutics, Inc., Annual General Meeting, Jul 02, 2024

Leap Therapeutics, Inc. Appoints Atricia Martin and Christian Richard to Board of Directors

Leap Therapeutics, Inc. Announces Appointment of Richard L. Schilsky, MD to its Board of Directors

Leap Therapeutics, Inc. Resigns Dr. Monica Bertagnolli, as Director

Insufficient new directors

Insufficient new directors

Recent updates

Leap Therapeutics, Inc., Annual General Meeting, Jul 02, 2024

Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP

Leap Therapeutics, Inc. to Present New Clinical Data from Part A of Defiance Study At the 2024 Asco Gastrointestinal Cancers Symposium

Leap Therapeutics, Inc. Announces Completion of Enrollment in Randomized Controlled Part C of the Distinguish Study of DKN-01 for the Treatment of Gastric Cancer Patients

Leap Therapeutics, Inc. Announces Initiation of Randomized Controlled Part B of the Defiance Study of DKN-01 in Colorectal Cancer Patients

Leap Therapeutics Announces Reverse Stock Split to Meet the Minimum Nasdaq Listing Price Per Share Requirements

Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

Leap Therapeutics, Inc. (NasdaqGM:LPTX) acquired Flame Biosciences, Inc from Acuta Capital Partners LLC, Adage Capital Management, L.P., Cormorant Asset Management, LP, Cormorant Asset Management, LP, Terra Magnum Capital Partners and others.

Leap Therapeutics, Inc. Appoints Atricia Martin and Christian Richard to Board of Directors

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.14 loss in 3Q 2021)

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

Leap Therapeutics, Inc. Announces First Patient Enrolled in Defiance Study of Dkn-01 for the Treatment of Colorectal Cancer Patients

Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 Distinguish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

Leap Therapeutics, Inc. Announces Appointment of Richard L. Schilsky, MD to its Board of Directors

Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq at the ESMO Congress

First half 2022 earnings released

Leap Therapeutics, Inc. Resigns Dr. Monica Bertagnolli, as Director

Leap Therapeutics and BeiGene, Ltd. Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer

Leap Therapeutics, Inc. to Present Initial Data from the Investigator-Sponsored Study of DKN-01 Plus Docetaxel in Patients with Prostate Cancer at the 2022 ASCO Annual Meeting

First quarter 2022 earnings released: US$0.092 loss per share (vs US$0.12 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Leap Therapeutics to Present Positive New Data from the Distinguish Study of DKN-01 Plus Tislelizumab at the Asco GI Cancers Symposium

Insufficient new directors

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.092 loss in 3Q 2020)

Leap Therapeutics to Present New Data from the Distinguish Study of Dkn-01 Plus Tislelizumab At the Esmo 2021 Congress

First half 2021 earnings released: US$0.24 loss per share (vs US$0.57 loss in 1H 2020)

First quarter 2021 earnings released: US$0.12 loss per share (vs US$0.55 loss in 1Q 2020)

Leap Therapeutics, Inc. Provides DKN-01 Development Update

Revenue misses expectations

New 90-day high: €2.18

New 90-day high: €2.00

New 90-day low: €1.27

Leap Therapeutics, Inc. Announces the Presentation of Clinical Data from Its Phase 1b/2a Clinical Trial of DKN-01 in Patients with Advanced Esophagogastric Cancer

New 90-day high: €1.84

Leap Therapeutics, Inc. announced that it has received $26.985796 million in funding from Perceptive Advisors LLC, BeiGene, Ltd., Baker Bros. Advisors LP

Leap Therapeutics, Inc. Announces FDA Fast Track Designation Granted to DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer

Leap Therapeutics and Beigene Announces First Patient Dosed in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer

New 90-day low - €1.50

New 90-day low - €1.52

Leap Therapeutics, Inc.(NasdaqGM:LPTX) dropped from Russell Microcap Value Index

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad